Uni-Bio Science Group Announces 2024 Interim Results
- Written by Viw Magazine
Achieved Record High Revenue of HK$273.6M and Net Profit of HK$67.4M
Further Penetration to Osteoporosis, Ophthalmology, and Medical Aesthetic Device Markets
HONG KONG SAR - EQS Newswire - 28 August 2024 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2024 (the "Period").
Further Penetration to Osteoporosis, Ophthalmology, and Medical Aesthetic Device Markets
HONG KONG SAR - EQS Newswire - 28 August 2024 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2024 (the "Period").
